摘要
目的提高喜炎平注射液临床使用安全性。方法选取2015年5月至2017年5月使用喜炎平注射液后发生不良反应的患者120例,收集患者的一般资料,包含年龄、性别、联合用药状况、病情和出现不良反应的种类等,对喜炎平注射液和不同药物的配伍疗效进行分析。结果患者年龄大于60岁和小于10岁是易感人群,与10~30岁、31~60岁年龄段对比,差异均有统计学意义(P<0.05);联合使用抗感染、呼吸系统与激素类药物出现不良反应的概率较高,其中抗感染药物的概率为35.00%,与其他类型药物对比,差异均有统计学意义(P<0.05);临床不合理用药中,联合3种及以上用药致使患者出现不良反应的比例最大,与超剂量、联合2种及以上用药和潜在的配伍不合理对比,差异均有统计学意义(P<0.05);不良反应主要包括皮肤不适、呼吸反应和心血管系统反应。结论对老年人和儿童要慎用喜炎平注射液,尽可能少与呼吸系统类、激素及抗感染类药物合用,以减少患者出现不良反应的概率并提高其临床安全性。
Objective To improve the safety of clinical use of Xiyanping Injection.Methods Totally 120 patients with adverse drug reactions induced by Xiyanping Injection from May 2015 to May 2017 in our hospital were selected,the basic data of clinical patients were collected,including age,sex,combination medication,disease status and the types of adverse drug reactions.The curative effect of the compatibility of Xiyanping Injection and different drugs was analyzed.Results Patients aged over 60 years old and younger than10 years old were susceptible to adverse drug reactions,compared with 10-30 years old and 31-60 years old group,the difference was statistically significant(P < 0.05).The combined use of anti-infection,respiratory and hormonal drugs has a higher incidence of adverse drug reactions,in which the probability of anti-infective drugs was 35.00%,compared with other types of drugs,the difference was statistically significant(P < 0.05).In clinical irrational drug use,the combination of three or more drugs resulted in the greatest proportion of adverse drug reactions,compared with over dosage,combined two or more drugs and potential compatibility,the differences were statistically significant(P < 0.05).The main adverse drug reactions included skin discomfort,respiratory reactions,and cardiovascular response.Conclusion The elderly and children should cautiously use Xiyanping Injection,which should as few as possible with the combined use of anti-infective,respiratory and hormonal drugs,in order to reduce the incidence rate of adverse drug reactions and improve the clinical safety of the patients.
作者
刘万里
张宪伟
张兵
Liu Wanli;Zhang Xianwei;Zhang Bing(The 11th Hospital of PLA, Yili, Xinjiang, China 835000;Institute of Toxicology and Pharmacy, Academy of Military Medical Sciences, Beijing,China 100850)
出处
《中国药业》
CAS
2017年第22期84-85,共2页
China Pharmaceuticals
关键词
喜炎平注射液
配伍禁忌
药品不良反应
合理用药
Xiyanping Inject ion
in compatibility
adverse drug reaction
rational drug use
